IberiaBank’s AstraZeneca AZN Stock Holding History

IberiaBank’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-3,907	Closed	-$309K	–	258
2018 Q3	$309K	Buy	+3,907	New	+$296K	0.04%	222
2013 Q4	–	Sell	-3,875	Closed	-$201K	–	143
2013 Q3	$201K	Sell	3,875 -439	-10%	-$22.1K	0.13%	150
2013 Q2	$204K	Buy	+4,314	New	+$220K	0.15%	133

Other funds holding AZN

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

IberiaBank's AZN Position: Q4 2018 in Review

IberiaBank sold out of AstraZeneca (AZN) in Q4 2018, closing a stake of 3,907 shares — an estimated $309K sold.

IberiaBank first reported a position in AZN in Q2 2013 and held it in 3 quarters. The position peaked at $309K in Q3 2018. 557 funds tracked by Wall St. Rank hold AZN as of Q4 2018.

IberiaBank reported no remaining AstraZeneca position as of Q4 2018 after selling out during the quarter.
IberiaBank sold 3,907 AstraZeneca shares in Q4 2018, an estimated $309K.
IberiaBank first reported a position in AstraZeneca in Q2 2013 and held it in 3 quarters.
IberiaBank's AstraZeneca position peaked at $309K in Q3 2018.
557 funds tracked by Wall St. Rank held AstraZeneca as of Q4 2018.

Based on IberiaBank's 13F filing for Q4 2018, filed 29 Jan 2019.